Inhibition of head and neck squamous cell carcinoma by Bruton’s tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells

Inhibition of head and neck squamous cell carcinoma by Bruton’s tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells

Abstract Head and neck squamous cell carcinoma (HNSCC) is one of the most diagnosed malignancies globally, with a 5-year survival rate of only 40–50%. Current therapies are limited to aggressive chemoradiotherapy combinations and disfiguring resection. Recent research has demonstrated that inhibitio...

Full description

Saved in:
Bibliographic Details
Main Authors: Anna R. Bopp, Felipe F. Lamenza, Puja Upadhaya, Nathan M. Ryan, Natalie Kazmierowicz, Pete P. Jordanides, Arham Siddiqui, Sherefuddin H. Pracha, Peyton Roth, O. Hans Iwenofu, Steve Oghumu
Format: Article
Language:English
Published: Springer 2025-05-01
Series:Cancer Immunology, Immunotherapy
Subjects:
HNSCC
Ibrutinib
T cells
Interleukin 10
Online Access:https://doi.org/10.1007/s00262-025-04081-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items